Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.43 |
| ▸ | ESR1 | P03372 | 2/20 | 0.42 |
| ▸ | ABCC9 | O60706 | 2/20 | 0.39 |
| ▸ | ABCC8 | Q09428 | 2/20 | 0.39 |
| ▸ | KCNJ11 | Q14654 | 2/20 | 0.39 |
| ▸ | KCNJ8 | Q15842 | 2/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | VDR | P11473 | 1/20 | 0.36 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.35 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5865830 | 0.76 | NR1H2 (0.51) | MEN1TSHRMAPK1KMT2ANR1H2 | |
| SCHEMBL5865852 | 0.75 | TSHR (0.52) | TSHRMAPK1NR1H2NR1I2NR1H3 | |
| SCHEMBL4610912 | 0.75 | MEN1 (0.40) | MEN1ALOX15TSHRMAPK1KMT2A | |
| SCHEMBL7256122 | 0.75 | MAPK1 (0.40) | MEN1ALOX15TSHRMAPK1KMT2A | |
| SCHEMBL2106514 | 0.74 | MAPK1 (0.47) | MEN1ALOX15TSHRMAPK1KMT2A | |
| SCHEMBL14015053 | 0.74 | ESR1 (0.49) | MEN1ALOX15TSHRMAPK1KMT2A | |
| SCHEMBL1813640 | 0.73 | NR1H2 (0.43) | MEN1TSHRMAPK1KMT2AHSD17B10 | |
| SCHEMBL3420846 | 0.72 | NR1H2 (0.43) | MEN1KMT2ANR1H2ABCC9ABCC8 | |
| SCHEMBL7767149 | 0.70 | CYP19A1 (0.56) | MEN1TSHRMAPK1KMT2AESR1 | |
| SCHEMBL13736869 | 0.70 | RORC (0.55) | MEN1TSHRKMT2ANR1H2NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1476423-B1 | ARYLSULFONAMIDOBENZYLIC COMPOUNDS | AMGEN INC (US) | 2008-10-15 | — | — | EP | disclosed |
| US-7326812-B2 | Lipid diseases; metabolism diosrders; antiproliferative agents | AMGEN INC. (US) | 2008-02-05 | — | — | US | disclosed |
| US-7071358-B2 | Arylsulfonamidobenzylic compounds | AMGEN INC. (US) | 2006-07-04 | — | — | US | disclosed |
| US-20060122239-A1 | Arylsulfonamidobenzylic compounds | TULARIK INC. | 2006-06-08 | — | — | US | disclosed |
| EP-1476423-A4 | ARYLSULFONAMIDOBENZYLIC COMPOUNDS | TULARIK INC (US) | 2005-12-14 | — | — | EP | disclosed |
| EP-1476423-A2 | ARYLSULFONAMIDOBENZYLIC COMPOUNDS | Tularik Inc. (US) | 2004-11-17 | — | — | EP | disclosed |
| US-20030229093-A1 | Arylsulfonamidobenzylic compounds | TULARIK INC. | 2003-12-11 | — | — | US | disclosed |
| WO-2003063576-A2 | ARYLSULFONAMIDOBENZYLIC COMPOUNDS | TULARIK INC. (US) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122239-A1 | Arylsulfonamidobenzylic compounds | FASN, ARSA, HSD17B4 | MEN1 2920/4885ALOX15 272/4885TSHR 1305/4885 |
| US-20030229093-A1 | Arylsulfonamidobenzylic compounds | FASN, ARSA, HSD17B4 | MEN1 2920/4885ALOX15 272/4885TSHR 1305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.